M
MID Labs
Excel at providing quality and innovative ophthalmic products that benefit the patient
About MID Labs
MID Labs, founded by Dr. Carl Wang in 1981, is a pioneering company in the field of ophthalmic surgical devices, specifically focusing on vitreoretinal surgery. Based in the San Francisco Bay Area, MID Labs has established itself as a global leader in the development and manufacture of advanced surgical instruments. The company's product line includes Vitreous Cutters, Bi Blade Vitreous Cutters, and the Single Step Cannula Insertion System, which are distributed in over 30 countries worldwide. MID Labs serves ophthalmic surgeons and healthcare providers, offering cutting-edge solutions that enhance surgical precision and patient outcomes. The company operates in the medical device market, with a business model centered around the research, development, and sale of high-quality surgical instruments. Revenue is generated through direct sales to healthcare institutions and partnerships with distributors. MID Labs is committed to preventing blindness caused by injuries and diseases such as diabetes, and its products have been used to help more than one million people globally. The company prides itself on its values of collaboration, initiative, integrity, and precision.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2014 | $51M | $204M | OrbiMed · Frontline BioVentures · Yuansheng BioVenture | — |
Growth signals
Latest recorded traffic for MID Labs is 130 monthly website visits, up 62.5% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
OrbiMed- FBFrontline BioVentures
Yuansheng BioVenture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MID Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MID Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







